Key result
Plasma SM 32:2 and ether lipids linked to subclinical atherosclerosis in type 1 diabetes.
Why the study?
To explore plasma lipidomics profiles in patients with type 1 diabetes and their potential associations with subclinical atherosclerosis.
Are specific plasma lipidomic profiles associated with subclinical atherosclerosis in patients with type 1 diabetes?
Comparison
Plasma lipidomics profiles evaluated for associations with subclinical atherosclerosis
Design
Cross-sectional observational study
Authors
Loading...
May inform risk stratification in type 1 diabetes; leaves open causal roles and preventive implications pending prospective data.
Observational (n=107)
Are specific plasma lipidomic profiles associated with subclinical atherosclerosis in patients with type 1 diabetes?
Specific plasma antioxidant molecules, including sphingomyelin and phosphatidylcholine, are associated with subclinical atherosclerosis in patients with type 1 diabetes, highlighting potential targets for personalized cardiovascular prevention.
Sojo et al. (2023) conducted an observational in Type 1 diabetes (T1DM) (n=107). Plasma lipidomics profiles was evaluated on Subclinical atherosclerosis and intima-media thickness. Plasma lipidomics profiles, specifically SM(32:2) and ether lipid species, were significantly and positively associated with subclinical atherosclerosis in patients with type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: